MLTX logo

MOONLAKE IMMUNOTHERAPEUTICS

MLTXNASDAQ
πŸ† #2345 by market capUS Equity
$11.09β€”
Last available close Β· quote unavailable
πŸ””
Track MLTX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 11.4%
14dβ–Ό 3.9%
30dβ–Ό 6.5%
ytdβ–Ό 15.8%
1yβ–Ό 12.4%
🏦Market Cap
$942M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
48
Weak

Trading Snapshot

Day Range
β€”
52-Week Range
$9.46 – $23.29
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
85.1M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-3.0
P/S Ratio
0.0x
EPS (TTM)
$-3.20
Dividend Yield
0.00%
Dilution (1yr)
+2.2%
MLTX logo

MOONLAKE IMMUNOTHERAPEUTICS

MLTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$245Mβ–² +71.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$196Mβ–² +67.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64.5Mβ–² +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$259Mβ–² +$81M YoY
StockOtter Β· stockotter.space

About MOONLAKE IMMUNOTHERAPEUTICS

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
48/100
Analyst data unavailable.

Latest News & Updates

News unavailable.